Results of liquid biopsy studies by next generation sequencing in patients with advanced stage non-small cell lung cancer: Single center experience from Turkey
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus, and Heart, 4th ed. Lyon, France: International Agency for Research on Cancer Press; 2015.TravisWDBrambillaEBurkeAPMarxANicholsonAGLyon, FranceInternational Agency for Research on Cancer Press2015Search in Google Scholar
Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the college of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018; 142(3): 321-346.LindemanNICaglePTAisnerDLArcilaMEBeasleyMBBernickerEHet alUpdated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the college of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology2018142332134610.5858/arpa.2017-0388-CPSearch in Google Scholar
Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014; 20(5): 548-554.NewmanAMBratmanSVToJWynneJFEclovNCModlinLAet alAn ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage201420554855410.1038/nm.3519Search in Google Scholar
Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, et al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res. 2016; 22(23): 5772-5782.ThompsonJCYeeSSTroxelABSavitchSLFanRBalliDet alDetection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA201622235772578210.1158/1078-0432.CCR-16-1231Search in Google Scholar
Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, et al. Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin Cancer Res. 2017; 23(17): 5101-5111.SchwaederléMCPatelSPHusainHIkedaMLanmanRBBanksKCet alUtility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma201723175101511110.1158/1078-0432.CCR-16-2497Search in Google Scholar
Sawada K, Kotani D, Bando H. The clinical landscape of circulating tumor DNA in gastrointerstinal malignancies. 2018; 8: 263. doi: 10.3389/fonc.2018.00263. eCol lection 2018.SawadaKKotaniDBandoH2018826310.3389/fonc.2018.00263eCol lection 2018Open DOISearch in Google Scholar
Esposito AR, Pasquale R, Fenizia F, Rachiglio AM, Roma C, Bergantino F, et al. The role of circulating free DNA in the management of NSCLC. Expert Rev Anticancer Ther. 2019; 19(1): 19-28.EspositoARPasqualeRFeniziaFRachiglioAMRomaCBergantinoFet alThe role of circulating free DNA in the management of NSCLC2019191192810.1080/14737140.2019.1548938Search in Google Scholar
Uchida J, Kato K, Kukita Y, Kumagai T, Nishino K, Daga H, et al. Diagnostic accuracy of non invasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA. Clin Chem. 2015; 61(9): 1191-1196.UchidaJKatoKKukitaYKumagaiTNishinoKDagaHet alDiagnostic accuracy of non invasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA20156191191119610.1373/clinchem.2015.241414Search in Google Scholar
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-celllung cancer. N Engl J Med. 2005; 353(2): 123-132.ShepherdFARodrigues PereiraJCiuleanuTTanEHHirshVThongprasertSet alErlotinib in previously treated non-small-celllung cancer2005353212313210.1056/NEJMoa050753Search in Google Scholar
Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomized, placebo controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2004; 366(9496): 1527-1537.ThatcherNChangAParikhPRodrigues PereiraJCiuleanuTvon PawelJet alGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomized, placebo controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)200436694961527153710.1016/S0140-6736(05)67625-8Search in Google Scholar
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3): 239-246.RosellRCarcerenyEGervaisRVergnenegreAMassutiBFelipEet alErlotinib versus standard chemotherapy as first line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial201213323924610.1016/S1470-2045(11)70393-XSearch in Google Scholar
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med. 2010; 363(18): 1693-1703.KwakELBangYJCamidgeDRShawATSolomonBMakiRGet alAnaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer2010363181693170310.1056/NEJMoa1006448Search in Google Scholar
Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial. Lancet Oncol. 2017; 18(10): 1307-1316.PlanchardDSmitEFGroenHJMMazieresJBesseBHellandÅet alDabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial201718101307131610.1016/S1470-2045(17)30679-4Search in Google Scholar
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw. 2015; 13(5): 515-524.EttingerDSWoodDEAkerleyWBazhenovaLABorghaeiHCamidgeDRet alNon-small cell lung cancer, version 6.2015201513551552410.6004/jnccn.2015.007125964637Search in Google Scholar
Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-Tan J, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib. Clin Cancer Res. 2015; 21(14): 3196-3203.MokTWuYLLeeJSYuCJSriuranpongVSandoval-TanJet alDetection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib201521143196320310.1158/1078-0432.CCR-14-259425829397Search in Google Scholar
Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: Circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014; 9(9): 1345-1353.DouillardJYOstorosGCoboMCiuleanuTColeRMcWalterGet alGefitinib treatment in EGFR mutated caucasian NSCLC: Circulating-free tumor DNA as a surrogate for determination of EGFR status2014991345135310.1097/JTO.0000000000000263422458925122430Search in Google Scholar
Reck M, Hagiwara K, Han B, Tjulandin S, Grohé C, Yokoi T, et al. ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: The ASSESS study. J Thorac Oncol. 2016; 11(10): 1682-1689.ReckMHagiwaraKHanBTjulandinSGrohéCYokoiTet alctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: The ASSESS study201611101682168910.1016/j.jtho.2016.05.03627468938Search in Google Scholar
Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: Meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013; 24(9): 2371-2376.DeardenSStevensJWuYLBlowersDMutation incidence and coincidence in non small-cell lung cancer: Meta-analyses by ethnicity and histology (mutMap)20132492371237610.1093/annonc/mdt205375533123723294Search in Google Scholar
Zhang X-C, Wang J, Shao G-G, Wang Q, Qu X, Wang B, et al. Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. Nat Commun. 2019; 10(1): 1772.ZhangX-CWangJShaoG-GWangQQuXWangBet alComprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients2019101177210.1038/s41467-019-09762-1646789330992440Search in Google Scholar
Song Z, Wang H, Yu Z, Lu P, Xu C, Chen G, et al. De novo MET amplification in Chinese patients with non-small-cell lung cancer and treatment efficacy with crizotinib: A multicenter retrospective study. Clin Lung Cancer. 2018; 20(2)): e 171-e176.SongZWangHYuZLuPXuCChenGet alDe novo MET amplification in Chinese patients with non-small-cell lung cancer and treatment efficacy with crizotinib: A multicenter retrospective study2018202e171e17610.1016/j.cllc.2018.11.00730554986Search in Google Scholar
Asao T, Takahashi F, Takahashi K. Resistance to molecularly targeted therapy in non-small-cell lung cancer. Respir Investig. 2019; 57(1): 20-26. doi: 10.1016/j.resinv. 2018.09.001. Epub 2018 Oct 4.AsaoTTakahashiFTakahashiKResistance to molecularly targeted therapy in non-small-cell lung cancer2019571202610.1016/j.resinv2018.09.001. Epub 2018 Oct 4Open DOISearch in Google Scholar
Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, et al. EGFR fusions as novel therapeutic targets in lung cancer. Cancer Discov. 2016; 6(6): 601-611.KonduriKGallantJNChaeYKGilesFJGitlitzBJGowenKet alEGFR fusions as novel therapeutic targets in lung cancer20166660161110.1158/2159-8290.CD-16-0075489390727102076Search in Google Scholar
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017; 376(7): 629-640.MokTSWuYLAhnMJGarassinoMCKimHRRamalingamSSet alOsimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer2017376762964010.1056/NEJMoa1612674676202727959700Search in Google Scholar
Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, et al. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treatment Rev. 2014; 40(8): 990-1004.RolfoCGiovannettiEHongDSBivonaTRaezLEBronteGet alNovel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors2014408990100410.1016/j.ctrv.2014.05.00924953979Search in Google Scholar
Linda K, Mikael J, Kjell G, Jonas N. Liquid biopsies in lung cancer — time to implement research technologies in routine care? Ann Transl Med. 2017; 5(13): 278.LindaKMikaelJKjellGJonasNLiquid biopsies in lung cancer — time to implement research technologies in routine care?201751327810.21037/atm.2017.04.12551580428758104Search in Google Scholar